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Abstract
Renal cell carcinoma (RCC) is a common malignancy following kidney transplantation. We 
describe RCC risk and examine RCC risk factors among US kidney recipients (1987-2010). The 
Transplant Cancer Match Study links the US transplant registry with 15 cancer registries. 
Standardized incidence ratios (SIRs) were used to compare RCC risk (overall and for clear cell 
[ccRCC] and papillary subtypes) to the general population. Associations with risk factors were 
assessed using Cox models. We identified 683 RCCs among 116,208 kidney recipients. RCC risk 
was substantially elevated compared with the general population (SIR 5.68, 95%CI 5.27-6.13), 
especially for papillary RCC (SIR 13.3 vs. 3.98 for ccRCC). Among kidney recipients, RCC risk 
was significantly elevated for blacks compared to whites (hazard ratio [HR] 1.50) and lower in 
females than males (HR 0.56). RCC risk increased with prolonged dialysis preceding 
transplantation (p-trend<0.0001). Risk was variably associated for RCC subtypes with some 
medical conditions that were indications for transplantation: ccRCC risk was reduced with 
polycystic kidney disease (HR 0.54), and papillary RCC was increased with hypertensive 
nephrosclerosis (HR 2.02) and vascular diseases (HR 1.86). In conclusion, kidney recipients 
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experience substantially elevated risk of RCC, especially for papillary RCC, and multiple factors 
contribute to these cancers.
Introduction
Approximately 17,000 kidney transplants were performed in the US in 2014, representing an 
increase of over 200% since 1988 (1,2). While kidney transplantation greatly improves 
survival and quality of life for patients with end-stage renal disease (ESRD), increased 
cancer risk is a major concern (3,4). Transplant recipients have an increased incidence of 
cancer compared to the general population (3-6). Excess risk is related to the need for 
immunosuppressive therapy to prevent rejection of the transplanted organ, and many of the 
subsequent cancers are caused by oncogenic viruses. Kidney recipients also have an 
approximate 6-fold increased incidence of renal cell carcinoma (RCC) (3,4,6), the most 
common urologic malignancy following kidney transplantation (7).
RCC comprises several major histologic subtypes including clear cell RCC (ccRCC, 
approximately 70% of cases in the general population), papillary RCC (10-15%), and 
chromophobe RCC (5%) (8,9). Each RCC subtype has distinct clinical and genetic 
characteristics, with ccRCC demonstrating a worse prognosis than other subtypes (8,9). 
Given the differences in presentation, RCC subtypes may also possess distinct etiologies.
Overall, established RCC risk factors in the general population include male sex, older age, 
African descent, excess body weight, cigarette smoking, and hypertension (10). ESRD 
patients treated with dialysis also have an elevated risk of RCC (11-13), which is at least in 
part related to the development of acquired cystic kidney disease (ACKD, a condition 
associated with kidney dysfunction that is characterized by the progressive development of 
multiple fluid-filled renal cysts) (14-16). At the time of kidney transplantation, the diseased 
native kidneys are usually left in situ, and most RCCs in kidney transplant recipients develop 
in the native kidneys rather than in the donor kidney (17).
To date, risk factors for RCC in kidney recipients have not been systematically assessed in a 
large population-based study. Some contributing factors may include the cause of underlying 
ESRD, other recipient characteristics, and specific immunosuppressive medications. 
Characteristics of kidney donors, such as donor type (deceased vs. living donor) or human 
leukocyte antigen (HLA) mismatch have rarely been assessed. Since kidney recipients are 
typically under heightened medical surveillance, the elevated RCC risk may also be partly 
due to detection bias, e.g., through screening or the use of computed tomography or 
ultrasound in medical evaluations. Surveillance would be expected to lead to detection of 
asymptomatic RCCs, so there would be an excess risk for local stage cancers and an absence 
of increased risk for cancers that are regionally advanced or metastatic (18,19).
Given the substantial burden of RCC in kidney transplant recipients, a better understanding 
of the risk factors for this cancer is needed to uncover carcinogenic mechanisms and identify 
ways to reduce morbidity and mortality. Previously we examined how kidney dysfunction, 
among a large population of US patients with ESRD, was associated with increased risk of 
kidney cancer (13). In the present study, we focus on examining the relationship of 
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established and suspected RCC risk factors among kidney transplant recipients with a 
functioning graft. We further investigate whether associations between these examined risk 
factors and RCC differ by histologic subtype.
Methods and Materials
Study Population, Outcomes, and Risk factors
The Transplant Cancer Match (TCM) Study has been described in detail previously 
(www.transplantmatch.cancer.gov) (6). Briefly, the TCM Study links the Scientific Registry 
of Transplant Recipients (SRTR) with 15 population-based US cancer registries (located in 
California, Colorado, Connecticut, Florida, Georgia, Hawaii, Iowa, Illinois, Michigan, New 
Jersey, New York, North Carolina, Seattle (Washington), Texas, and Utah), which 
collectively provide ascertainment of cancers for 47% of the US transplant population 
(1987-2010). The SRTR contains information on all solid organ transplant recipients, 
including demographic characteristics, reason for transplantation, characteristics of organ 
donors, and initial immunosuppressive regimen.
Our study population consisted of kidney recipients in the TCM Study who received a 
transplant between 1987 and 2010. We restricted analysis to non-Hispanic whites, non-
Hispanic blacks, Hispanics, and Asian/Pacific Islanders to allow comparison with general 
population cancer incidence. We further excluded subjects if they had received a previous 
transplant, received a multi-organ transplant, or had a previous kidney cancer diagnosis 
documented in the cancer registries.
Subjects were considered at risk for cancer beginning with transplantation or start of cancer 
registry coverage, whichever came last (95.9% of the cohort were followed from the time of 
transplantation, while the median time from transplantation to start of follow-up was 1.9 
years for the 4.1% who entered late). Recipients were followed until development of RCC 
(as identified in cancer registries), death, failure of the transplanted kidney, subsequent 
transplant, loss to follow-up (i.e., no longer followed by transplant centers), or end of cancer 
registry coverage, whichever came first; all patients exited by December 31, 2010. We 
identified incident cases of RCC using International Classification of Diseases for Oncology 
Third Edition (ICD-O-3) topography code C64.9 and used with morphology codes to define 
subtypes: 8260 (papillary), 8310 (clear cell), 8312 (not otherwise specified), or 8316-18 
(cyst-associated, chromophobe, sarcomatoid, and spindle cell). We performed analyses for 
RCC overall and separately for ccRCC and papillary RCC; examination of other RCC 
histologic subtypes was not feasible due to small numbers. For a subset of six cancer 
registries, we also searched clinical case abstracts and pathology reports for any mention of 
whether the RCC was in the donor or native kidney.
Recipient and donor characteristics were ascertained from the SRTR. For duration of 
dialysis prior to transplant (i.e., vintage), we ignored dialysis prior to 1972 (the year the US 
Congress approved Medicare reimbursement for dialysis) to truncate extreme values for 
vintage for a few recipients (20). We categorized the primary reason for kidney transplant 
into the following categories: glomerular diseases, diabetes mellitus, hypertensive 
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nephrosclerosis, polycystic kidney disease, vascular diseases, tubular/interstitial diseases, 
congenital/familial/metabolic disorders, and other/unknown conditions.
Statistical analysis
We compared RCC risk in kidney recipients to the general population using standardized 
incidence ratios (SIRs). SIRs were calculated by dividing the number of observed cases by 
the number expected, based on general population rates specific to 5-year age group, sex, 
race/ethnicity, calendar year, and cancer registry. We estimated SIRs for RCC overall and for 
clear cell and papillary subtypes. We also assessed SIRs by tumor stage (local: tumor that is 
within the organ of origin; regional: tumor that extends beyond the limits of the organ of 
origin to surrounding tissues; distant: tumor that is metastatic; and unknown) and grade (low 
[grades I and II] and high [III and IV]). Based on the observed and expected counts, RCC 
cases in the transplant population were more likely to have a classified histologic subtype 
than cases in the general population. This difference could bias the SIRs for the specified 
subtypes upwards. We therefore adjusted for this difference by reducing the expected count 
for unspecified histologic subtypes and proportionately increasing the expected counts for 
the specified subtypes (see Table S1).
We used Cox proportional hazards models, with time since transplant as the time metric, to 
calculate hazard ratios (HRs) assessing risk factors for RCC overall, ccRCC, and papillary 
RCC. HRs relating primary reason for transplant to RCC incidence were evaluated using 
effect parameterization, which compares each category to the average of all categories 
combined (21). We assessed the proportional hazards assumption graphically and by adding 
interaction terms between each risk factor and time since transplant; no evidence of 
violations against proportionality was found. We selected a final model by simultaneously 
including all risk factors that were significant in univariate models, then removing variables 
that were no longer significant in the multivariate model. Final models varied for ccRCC and 
papillary RCC based on the variables that were significant.
We also graphically illustrate RCC risk as a function of time since transplant, using a 
flexible parametric procedure to model the hazard as a linear combination of cubic B-splines 
(22). This technique generates smaller mean square errors than non-parametric methods and 
provides smooth estimates without making strong parametric assumptions. Additionally, to 
describe the absolute risk of a transplant recipient developing RCC during follow-up while 
taking into consideration the competing risk of death, we depict cumulative incidence curves 
for RCC overall and for papillary and clear cell subtypes; only recipients followed from 
transplantation are included in this analysis. We conducted all analyses using SAS Version 
9.2 (SAS Institute, Cary, NC, USA) and MATLAB. Statistical tests were determined 
significant at a two sided p-value<0.05 and were not adjusted for multiple comparisons.
Results
We assessed 116,208 kidney recipients followed for 595,352 person-years (median 4.2 
years; range: 0.003-23.1) (Table 1). Nearly 60% were male, and the average age at transplant 
was 45 years. The majority of subjects were white (52%), and 30% had a normal body mass 
index (BMI 18.5-24.9 kg/m2; 17% had missing data on BMI). Prior dialysis was common 
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(89%) with an average vintage of 2.7 years before transplant. The three most common 
indications for a kidney transplant were glomerular diseases (29%), diabetes mellitus (23%), 
and hypertension (18%). Approximately two-thirds of recipients (63%) received their kidney 
from a deceased donor.
Patients exited the study for a variety of reasons including: RCC (N=683, 0.6%), death 
(N=18,022, 15.5%), graft failure (N=27,742, 23.9%), retransplantation (N=1,035, 0.9%), 
loss to follow-up by the SRTR (N=12,664, 10.9%), or end of cancer registry coverage 
(N=56,062, 48.2%). Differences in select patient characteristics by exit reason are displayed 
in Table S2. Patients who exited because of death were more likely to be older, white, have 
had dialysis prior to transplant, have diabetes mellitus as an indication for transplant, and 
receive a kidney from a deceased donor compared to patients who exited for other reasons. 
Patients who exited because of graft failure or retransplantation were more likely than other 
patients to be black, and they were also likely to have had prior dialysis and to have received 
a deceased donor kidney. Patients with glomerular disease were over-represented among 
patients who exited due to loss to follow-up by SRTR. Patients who exited due to the end of 
cancer registry coverage were transplanted in the most recent calendar years.
A total of 683 incident cases of RCC were identified among transplant recipients. By 
histology, clear cell, papillary, and chromophobe RCCs comprised 32%, 28%, and 2% of 
cases, respectfully, while 2% of cases had other specified histologic subtypes of RCC and 
36% of cases had unspecified histologic subtypes. Overall, RCC risk was elevated 5.7-fold 
compared with the general population (SIR 5.68, 95% CI 5.27-6.13) (Table 2). Notably, the 
risk of papillary RCC was much more elevated than for ccRCC (SIR 13.3 vs. 3.98). 
Significantly elevated RCC risk was observed across all stage and grade categories, although 
higher SIRs were observed for local stage cancers (SIR 6.94) compared to regional stage 
(SIR 3.27) or distant stage cancers (SIR 2.97), and for low grade (SIR 6.69) versus high 
grade cancers (SIR 3.95). For each histologic subtype, the patterns according to stage and 
grade mirrored those for RCC overall.
Among 96 RCC cases for which cancer registry data were available, 85 cases (89%) were in 
a native kidney, and only 11 (11%) were noted to arise in the donor kidney. The histologic 
subtypes of tumors in the donor kidney were: 55% (N=6) clear cell, 27% (N=3) papillary, 
9% (N=1) chromophobe, and 9% (N=1) other/unspecified.
We assessed risk factors in univariate models to identify candidate variables to include in 
multivariate models (not shown). Table 3 shows risk factors that were significantly 
associated with at least one outcome (RCC, ccRCC, or papillary RCC) in multivariate 
models. Irrespective of histologic subtype, we observed reduced cancer risk among females 
compared to males (HRs 0.45-0.64). Risk increased with increasing age at transplant (RCC 
and ccRCC p-trends<0.0001, papillary RCC p-trend=0.01), and risk was higher following 
transplants in more recent calendar years (p-trends<0.0001). Compared to white recipients, 
Asians/Pacific Islanders had a 40% decreased risk while blacks had a 50% increase in risk 
for RCC; the increased risk among blacks was stronger for papillary RCC (HR 2.79).
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RCC risk increased with increasing dialysis vintage (p<0.0001), with the trend more 
apparent for papillary RCC (p=0.03) than ccRCC (p=0.08). Compared to the average kidney 
recipient, recipients transplanted for diabetes mellitus had reduced risk of RCC (HR 0.77), 
and risk was increased for recipients with glomerular diseases (HR 1.24), hypertensive 
nephrosclerosis (HR 1.55), and vascular diseases (HR 1.53). For ccRCC, reduced risk was 
observed for recipients with polycystic kidney disease (HR 0.54). Strong associations with 
risk were seen for papillary RCC with hypertensive nephrosclerosis (HR 2.02) and vascular 
diseases (HR 1.86).
Induction therapy with polyclonal antibodies and interleukin 2 (IL2) antagonists was 
associated with elevated risks for ccRCC (HR 1.36) and papillary RCC (HR 1.51), 
respectively. Among recipients who received a kidney transplant from a female versus male 
donor, we observed reduced risk for RCC (HR 0.86), specifically for papillary RCC (HR 
0.71). In contrast, an association of risk with increasing donor age was observed for RCC 
overall (p-trend 0.001) and ccRCC (p-trend 0.001). No significant associations with BMI, 
other induction or maintenance medications, HLA mismatch, cold ischemic time, and other 
donor characteristics (deceased vs. living donor, race, BMI) were observed (see adjusted 
HRs, Table S3).
Figures 1 illustrates the risk of RCC as a function of time since transplant. For RCC overall 
(Figure 1A), risk followed a biphasic pattern: risk was high immediately after transplant, 
decreased to a minimum approximately 2.5 years after transplant, and then rose steadily over 
the following years. Similar results were observed for ccRCC and papillary RCC separately, 
although the biphasic pattern appeared stronger for papillary RCC (Figures 1B). Biphasic 
patterns were observed for localized RCC and for both low grade and high grade RCCs; risk 
for regional/distant RCC appeared somewhat constant over time (Figures 1C and 1D).
Figure 2 illustrates the absolute risk of RCC as a function of time since transplant. At 5 
years after transplant, 0.5% of recipients developed RCC, and 1.0% developed RCC by 10 
years. By histology, very little difference in cumulative incidence was observed for ccRCC 
and papillary RCC during follow-up.
Discussion
In our large population-based study of US kidney recipients, we observed a nearly 6-fold 
overall increased risk of RCC. Notably, a much greater elevation in risk was seen for the 
papillary RCC histologic subtype than for the clear cell subtype. RCC risk was highest in 
individuals who had had prolonged dialysis prior to transplantation, and it varied separately 
for ccRCC and papillary RCC according to the medical conditions that were the indication 
for transplantation. Based on our evaluation of a sample of cases, the great majority arose in 
a native kidney, with only 11% of the RCCs occurring in the donor kidney. We also observed 
a biphasic onset of RCC following transplant: a high risk immediately after transplant, a fall 
in risk until roughly 2.5 years after transplant, and then a subsequent gradual increase with 
time.
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The 16-fold increase in risk for papillary RCCs among kidney recipients is noteworthy. In 
the general population, ccRCC and papillary RCC comprise about 70% and 10-15% of RCC 
cases, respectively (8). In contrast, recent studies indicate an overrepresentation of papillary 
RCCs among kidney recipients, typically reported to comprise more than 30% of cases 
(14,23-26). Most prior studies were small (i.e., they included fewer than 50 RCCs in 
recipients) and were based at single institutions (14,23,25,26). Our study, which is much 
larger, confirms that papillary RCCs are overrepresented in kidney transplant recipients 
(28% of our cases), and it provides the first SIR estimate quantifying the markedly elevated 
risk for this subtype.
The observed association with vintage, which was stronger for the papillary than clear cell 
subtype, suggests that processes that occur during dialysis contribute to RCCs that arise after 
kidney transplant. A large proportion of RCCs in dialysis patients are also classified as 
papillary RCCs (27). The biological mechanisms that contribute to the development of RCC 
in individuals with ESRD are believed to differ from those for RCCs that arise in the general 
population. For example, sporadic RCCs, which predominantly consist of the clear cell 
subtype, manifest genetic or epigenetic inactivation of the von Hippel-Lindau (VHL) tumor 
suppressor gene in greater than 90% of cases (28), yet RCCs in ESRD patients typically do 
not exhibit this VHL mutation (29). In contrast, papillary tumors that arise in ESRD patients 
exhibit allelic duplications of chromosomes 7 and 17, accompanied by activation of the 
MET proto-oncogene on chromosome 7q (30).
Although kidney function typically improves soon after transplant, some early RCC tumors 
likely arise in the native kidney as a result of malignant transformation of renal cysts that 
had developed before transplantation as a part of ACKD (14-16). According to the National 
Institute of Diabetes and Digestive and Kidney Diseases, about 20% of patients who start 
dialysis have ACKD, 60-80% of patients on dialysis for four years develop ACKD, and 90% 
of patients with dialysis for at least eight years develop ACKD (31). Of patients with ACKD, 
roughly 10-20% develop RCCs (31,32), which tend to be large and multifocal (33). The high 
incidence of RCC among dialysis patients may be related to ACKD and effects of uremic 
toxins which may lead to DNA alterations (34), while the early decline following receipt of 
a kidney transplant, especially for papillary RCC, may be due to clearance of these toxins 
(13). Of note, there is also an elevated risk of late-onset kidney cancer, observed in our 
investigation and also in studies that included recipients of other transplanted organs (3,6), 
which is not well understood.
The absence of an increased risk of RCC among HIV-infected individuals suggests that the 
excess in transplant recipients is not a consequence of immune deficiency per se (35). 
Calcineurin inhibitors (i.e., cyclosporine and tacrolimus), which are widely used as 
maintenance immunosuppressive medications, exhibit nephrotoxic effects that result acutely 
in the reduction of glomerular filtration rate and, over time, in tubular atrophy and interstitial 
fibrosis (36). Calcineurin inhibitors and other maintenance medications (e.g., azathioprine) 
have additional biological effects that may promote the development of cancer (37). 
Although we did not see associations between specific maintenance immunosuppressive 
medications and RCC risk, it remains possible that their effects contributed to the increase in 
RCC, as most recipients were exposed to one calcineurin inhibitor or the other, and we were 
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limited by our inability to assess dose and duration of use of these medications. Recipients 
of other transplanted organs, also on maintenance immunosuppressive medications, exhibit 
an elevated risk of kidney cancer, although it is not as high as seen in kidney recipients (6). 
Moreover, we observed increased risk related to induction therapy with polyclonal 
antibodies (for ccRCC) and IL2 antagonists (for papillary RCC), but the explanations for 
these findings are unclear.
The incidence of RCC has appeared to increase in the US and globally over the past few 
decades (10,38). Much of this increase is related to a rise in detection of asymptomatic small 
tumors, and up to 50% of RCC cases are speculated to be over-diagnosed (18,19,38). 
Incidentally detected tumors, on average, are smaller and diagnosed at a lower stage than 
symptomatic tumors (18,19). Because kidney recipients are closely followed by transplant 
providers, work-up for graft dysfunction, rejection, or other medical conditions may lead to 
incidental detection and perhaps over-diagnosis of RCC. These medical evaluations may be 
partly responsible for the excess risk of RCC observed in our study and others. Indeed, in 
our investigation, RCC risk, irrespective of histologic subtype, was greatest for local stage 
and low grade tumors. Incidental detection of RCCs may also explain the higher RCC risk 
observed in our study population following transplants in more recent calendar years. 
Importantly, however, the significantly elevated risks of advanced stage and high grade RCC 
imply that intensive medical surveillance does not entirely explain the excess.
Compared to the average kidney recipient in our population, patients with glomerular 
diseases, vascular diseases, and hypertensive nephrosclerosis as the indication for transplant 
had an elevated risk of RCC. Glomerular diseases, such as glomerulonephritis, IgA 
nephropathy, membranous nephropathy, focal glomerulosclerosis, and amyloidosis are 
common causes of ESRD (1) and have been linked in previous studies to increased RCC risk 
in transplant recipients (12,39). In glomerular diseases, loss of podocytes that envelope the 
glomerular capillaries can often lead to renal cysts, and several studies show that glomerular 
diseases are more common among ACKD patients than non-ACKD patients (40,41). 
Moreover, vascular diseases may increase RCC risk in ESRD patients by reducing blood 
flow to the kidney cortex. Arteriopathic renal diseases have previously been associated with 
increased kidney cancer risk in dialysis patients (11,12). In our study, vascular diseases were 
strongly associated with papillary RCC, but not ccRCC. Interestingly, glomerular and 
vascular changes are hallmarks of hypertensive nephrosclerosis (42). Because nearly all 
ESRD patients are hypertensive, determining whether hypertension is the cause or result of 
ESRD can be difficult. Nevertheless, hypertension is the second most common cause of 
ESRD and has been associated with increased RCC risk in the general population (10) and 
in ESRD patients (4,11).
It is less clear why patients with ESRD due to diabetes or polycystic kidney disease had a 
lower risk of RCC compared to other kidney recipients, although similar findings have been 
reported previously (11,43). It has been speculated that protective cellular mechanisms, 
triggered by the formation of cysts in patients with polycystic kidney diseases, may prevent 
malignant transformation (43). This hypothesis is supported by the observation that germline 
mutations in PKHDI, the gene responsible for autosomal recessive polycystic kidney, protect 
against colorectal cancer (44). Furthermore, nephrectomy at the time of transplantation may 
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be more likely among recipients with polycystic kidneys than in other recipients, decreasing 
subsequent risk of RCC (43).
As expected, patterns of elevated RCC risk in our population were consistent with other 
known risk factors (10), including increasing age, male sex, and African descent. 
Additionally, we observed associations with donor age and donor male sex. Our finding for 
donor age, which has been observed previously (16), was adjusted for recipient age, 
suggesting that the variable is an independent RCC risk factor. Older and male donors may 
carry a higher risk of having pre-neoplastic kidney damage, but the relevance of this fact is 
uncertain, as only a minority of RCCs occurred in donor kidneys. The explanation for the 
observed association between donor sex and RCC is unclear. While the lack of association 
between elevated BMI and RCC may seem surprising at first, we note that our investigation 
was restricted to ESRD patients, and a low BMI in this population may be a marker of 
generally poor health (45).
Strengths of our study include its population-based design, large size, and representative 
sampling of the US transplant population. To our knowledge, this is the first study to provide 
SIR estimates for histologic subtypes of RCC among kidney transplant recipients, thereby 
quantifying the excess risk for papillary and clear cell RCC. Our ability to examine a range 
of RCC risk factors is an additional strength. Several limitations should also be noted. While 
we had a large number of RCC cases overall, analyses by histologic subtype may have been 
underpowered for some risk factors. We were unable to classify RCC subtype for 
approximately one-third of cases; however, the percentage of unknown tumor subtypes in 
our study is smaller than that in the general population. Also, we lacked data on smoking, 
which is a risk factor for RCC (10), and smoking may partly explain the elevated risks seen 
with hypertensive nephropathy and vascular disease. We also did not have data on the dose 
and duration of use for maintenance therapy drugs, which limits our ability to make firm 
conclusions about their effects. Since information on screening was unavailable, we were 
unable to assess whether RCC cases were incidentally or symptomatically diagnosed.
We examined risk factors for RCC in a cohort of transplant recipients who were also at risk 
of other competing outcomes, including graft failure, retransplantation, and death. A modest 
fraction of patients (10.9%) were lost to follow-up by the transplant centers reporting to the 
SRTR. As shown in Table S2, the characteristics of patients who exited for various reasons 
differed. Nonetheless, the HR estimates from our regression models, which measure the 
associations with risk factors for RCC, are correctly estimated under the assumption the 
hazard of RCC is independent of the hazard for the other outcomes conditional on the 
covariates in the models. Lastly, since we made multiple comparisons without adjustment, 
some associations may be due to chance. However, chance is an unlikely explanation for the 
strongly elevated risks shown in Table 2 or the most significant associations with RCC risk 
factors in Table 3.
Our estimates of absolute risk indicate that approximately 0.5% and 1.0% of kidney 
recipients are diagnosed with RCC within 5 and 10 years after transplant, respectively. A 
fraction of these cases were localized tumors and may represent over-diagnosis of cases 
detected incidentally through clinical evaluations or by screening efforts already in place in 
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some transplant programs. Thus, it is difficult to assess whether additional screening for 
RCC should be directed at the overall kidney transplant population. Nonetheless, it will be 
important to evaluate these issues formally and determine whether certain subgroups of 
kidney recipients predicted to be at highest risk of RCC would benefit from targeted 
screening.
In summary, kidney transplant recipients experience a disproportionately greater incidence 
of RCC compared to the general population, and the elevation is substantially higher for 
papillary than for clear cell tumors. Our results indicate that RCC and its histologic subtypes 
are associated with complex multifactorial etiologies, involving elements related to 
demographics, medical indications for transplantation, and kidney dysfunction (e.g., as 
indicated by duration of prior dialysis). Additional studies that consider how clinical, 
environmental, and genetic factors modify cancer risk among kidney recipients are needed to 
identify the precise mechanisms involved in the malignant transformation and progression of 
RCC.
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Figure 1. Hazard of RCC as a function of time since kidney transplant
Results are shown for: (A) RCC overall, (B) according to histologic subtypes (clear cell and 
papillary RCC), (C) according to stage (local and regional/distant RCC), and (D) according 
to grade (low and high grade). Hazards were estimated using cubic B-splines. The vertical 
axis shows the hazard in units of “per 1000 person-years”. RCC, renal cell carcinoma.
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Figure 2. Cumulative incidence of RCC, overall and by histology
Results are shown for RCC overall (dashed black and gray line), clear cell RCC (gray line), 
and papillary RCC (black line). Note that the vertical axis is truncated and reaches a 
maximum of 3%. RCC, renal cell carcinoma.
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Table 1
Selected characteristics of kidney transplant recipients
Characteristics N % 1
Overall 116,208 100.0
Sex
 Male 69,377 59.7
 Female 46,831 40.3
Age at transplant, years
 <30 19,696 17.0
 30-<40 19,552 16.8
 40-<50 25,881 22.3
 50-<60 27,935 24.0
 60+ 23,144 19.9
Calendar year of transplant
 <1995 19,740 17.0
 1995-<2000 26,360 22.7
 2000-<2005 32,450 27.9
 2005+ 37,658 32.4
Race
 White 60,064 51.7
 Black 27,442 23.6
 Hispanic 20,778 17.9
 Asian/Pacific Islander/Hawaiian 7,924 6.8
Body mass index (kg/m2)2
 10-<18.5 (underweight) 5,601 4.8
 18.5-24.9 (normal) 34,808 30.0
 25-29.9 (overweight) 31,580 27.2
 30+ (obese) 23,981 20.6
 Missing 20,238 17.4
Dialysis prior to transplant
 No 12,304 10.6
 Yes 102,817 88.5
 Missing/Unknown 1,087 0.9
Duration of dialysis (vintage), years
 0 (no dialysis) 12,304 10.6
 < 1 23,772 20.5
 1-<2 23,476 20.2
 2-<3 16,867 14.5
 3+ 38,702 33.3
 Missing/Unknown 1,087 0.9
Indication for transplant
 Glomerular Diseases 33,256 28.6
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Characteristics N % 1
 Diabetes mellitus 26,377 22.7
 Hypertensive Nephrosclerosis 20,567 17.7
 Polycystic Kidney Disease 10,680 9.2
 Tubular/Interstitial Diseases 5,994 5.2
 Vascular Diseases 4,513 3.9
 Congenital/Familial/Metabolic Disorders 3,676 3.2
 Other/Unknown Conditions 11,145 9.6
Donor type
 Living 42,928 36.9
 Deceased 73,280 63.1
Abbreviations: N- number; std- standard deviation
1
Frequencies may not sum to 100% due to rounding.
2
140 subjects with a body mass index <10kg/m2 or >100kg/m2 were assigned a missing value.
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